Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial
Top Cited Papers
- 20 February 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 395 (10227), 878-887
- https://doi.org/10.1016/s0140-6736(20)30258-0
Abstract
No abstract availableKeywords
Funding Information
- Alberta Innovates - Health Solutions
- Medtronic (62/086,077)
- Covidien
- Heart and Stroke Foundation of Canada
- Alberta Innovates
- National Institute of Neurological Disorders and Stroke
- Canadian Institutes of Health Research
This publication has 34 references indexed in Scilit:
- A Translational Paradigm for the Preclinical Evaluation of the Stroke Neuroprotectant Tat-NR2B9c in Gyrencephalic Nonhuman PrimatesScience Translational Medicine, 2012
- Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brainNature, 2012
- Minimal sufficient balance—a new strategy to balance baseline covariates and preserve randomness of treatment allocationStatistical Methods in Medical Research, 2012
- Update of the Stroke Therapy Academic Industry Roundtable Preclinical RecommendationsStroke, 2009
- Effectiveness of PSD95 Inhibitors in Permanent and Transient Focal Ischemia in the RatStroke, 2008
- Reliability of the Modified Rankin Scale Across Multiple RatersStroke, 2005
- Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein InteractionsScience, 2002
- Tissue Plasminogen Activator for Acute Ischemic StrokeThe New England Journal of Medicine, 1995
- Domain Interaction Between NMDA Receptor Subunits and the Postsynaptic Density Protein PSD-95Science, 1995
- Measurements of acute cerebral infarction: a clinical examination scale.Stroke, 1989